First demonstration of the proof-of-principle for boron neutron capture therapy of cancer, arthritis and radiation mediated surgery (BNCT).

Discrete molecular (monodisperse) nanoparticles which carry multiple copies of, or a combination of, diagnostic and therapeutic agents for cell-specific delivery to malig-nant cells.

F A C U L T Y

M. Frederick Hawthorne, Ph.D.

Director

Mark W. Lee, Jr., Ph.D.

Assistant Director

Satish Jalisatgi, Ph.D.

Director of Research Operations

Alexander Safronov, Ph.D.

Research Assistant Professor

Lalit Goswami, Ph.D.

Research Assistant Professor

Yulia Sevryugina, Ph.D. Research Assistant Professor

Lixin Ma, Ph.D.

Assistant Professor

Drug Delivery

Boron Neutron Capture Therapy of Cancer

Development of advanced chemical storage systems for hydrogen storage based upon nanotechnology and hy-dride chemistry.

Design, synthesis and characterization of new, high-energy materials for en-ergy storage in structural units ranging from nano dimensional to macroscale.

Development of nano-sized molecular motors with biomedical applications.

Development of catabolism-resistant pharmaceuticals based on carborane surrogate chemistry.

Molecular Motors

International Institute of Nano and Molecular Medicine

I²NM² is engaged in multifaceted research projects involving the creation of novel boron-containing materials, devices and agents enhanced by nanotechnology with applications in

medicine, related materials science and beyond. Research highlights include:

Chemical Hydrogen Storage

1514 RESEARCH PARK DR. COLUMBIA MO 65211 573-882-7016 WWW.NANOMED.MISSOURI.EDU

Drug Delivry

About the Director

Institute Facts

biomedicine, catalysis and materials applica-tions. An ongoing ob-jective is the develop-ment of boron neutron capture therapy of can-cer (BNCT) which Haw-thorne will continue at the University of Mis-souri nuclear reactor and supporting facilities.

For 32 years, Hawthorne served as the Editor-in-Chie f o f Inorgan ic Chemistry published by The American Chemical Society. Hawthorne has been honored by

Fred Hawthorne, Ph.D., and founding Director of the International Insti-tute of Nano and Mo-lecular Medicine, came to MU from the Univer-sity of California, Los Angeles in 2006.

Hawthorne has led in the creation of the new field of polyhedral bo-r a n e c h e m i s t r y (carboranes, polyhedral borane anions, metal-lacarboranes and metal-laboranes). These building blocks are find-ing use in nanoscience,

numerous national and international awards, honorary degrees and lectureships. He was the co-winner of the King Faisal International Prize in Science (2003), the highest scientific award of the Islamic world. In 2009 Haw-thorne was named Priestley Medalist, the premier award of the American Chemical So-ciety. He has published over 500 peer-reviewed papers and he holds 35 patents.

the Dalton Cardiovascular Research Center, includ-ing small animal facilities. I²NM² is housed in its own 30,000 f t ² laboratory building in Reactor Park adjacent to the MURR and the Dalton Cardio-vascular Research Cen-ter. The building houses several state of the art synthetic and analytical chemistry laborator ies i nc l ud i ng wo r l d - c l as s mass spectrometry facili-ties and a nuclear mag-netic resonance labora-tory. In addition to institute-owned facilities and in-strumentation, the center will have access to sev-eral university instru-mentation core facilities. These include additional NMR instrumentat ion, including 600 and 800 MHz NMR spectrome-ters, an electron micros-copy facility with SEM, TEM and atomic force microscopy center.

The International Institute of Nano and Molecular Medicine (I²NM²) is a new campus-wide research center dedicated to the discovery and application of fundamental and trans-lational medical science based upon previously unexp lo red chemis t r y combined with nanotech-nology and the biosci-ences. I²NM² will shortly become the international leader in the reinvigorated field of boron neutron capture therapy (BNCT), a cell-selective binary radiation method for cancer, arthri-tis and evolving non-invasive surgical proto-cols. The BNCT program will be conducted with the dedicated neutron source recently constructed at the University of Missouri R e s e a r c h R e a c t o r (MURR; the most power-ful university-based re-search reactor in the world) and the use of the life sciences laboratory of

The unique strength of I²NM² is its new ap-proach to medical inven-tions and its developing position as the strongest research facility for the development of boron neutron capture therapy of cancer in the world. These efforts are sup-po r ted by superb l y equipped laboratories with great strength in chemical synthesis cou-pled with nanoscience, b io log ica l chemis t r y , radiation biology and medicine. I²NM² will truly serve translational medi-cine. The Institute has been funded by the NIH, DOE, NSF, and Honeywell. and shares dual-use research projects with its subsidi-ary, Center for Borane Technology supported by the US Army (Picatinny Arsenal) and partnered with I2NM2.

Dr. M. Frederick Hawthorne

INTERNATIONAL INSTITUTE OF NANO AND MOLECULAR MEDICINE